Healthcare industry

Press release - 29/09/2009

Spectacular celebrations at Vetter’s high-tech company site

On September 25th Vetter a specialist of aseptically pre-filled application systems officially opened its new Ravensburg South Mariatal production plant. 2800 guests were invited to the official launch and the company also publicised further important financial highlights over the last five years Vetter has been able to increase its sales volume by 70 million euros to 250 million euros.

Vetter Pharma Fertigung a Ravensburg-based specialist in the production of aseptically pre-filled injection systems is strengthening its commitment to the North American market. Laupheim-based Rentschler Biotechnologie a contract research organisation that has been continuously expanding since 2006 has further investment plans.

"Faster Development of Safer Medicines through Translational Safety Biomarkers": On September 14, 2009, the Safer And Faster Evidence-based Translation (SAFE-T) consortium project under the EU Innovative Medicines Initiative - Joint Undertaking (IMI-JU) was presented at the EUROTOX 2009 conference in Dresden. The consortium announces the start of work to qualify biomarkers for drug-induced kidney, liver and vascular injury in…

Press release - 13/08/2009

Sygnis published its financial results for the first quarter of 2009/2010

SYGNIS Pharma AG published its financial results for the first quarter of the fiscal year 2009/2010, which ended on 30 June 2009.

Press release - 29/06/2009

Research Prize for Clinical Pharmacology in Ulm

Julia Kirchheiner, a professor of Clinical Pharmacology at the Institute of Natural Medicine and Clinical Pharmacology, University of Ulm, in Germany, was awarded the Utrecht Award for Excellence in Pharmaceutical Research, 2009. The international prize is awarded once every two years to non-University of Utrecht scientists who have a proven record over years of excellent research vision and leadership of improving drug therapy or safety.

Press release - 29/06/2009

Vetter strengthens Ravensburg company site

Vetter Pharma, a leading provider of aseptically pre-filled injection systems, has completed the installation of several new automatic packaging lines at the company’s new packaging services facility. The packaging facility allows Vetter to package its injection systems for delivery to its clients. The building, which cost 20 million euros to build, has room for 200 employees.

Press release - 22/06/2009

SYGNIS makes further progress in the 2008/2009 fiscal year

SYGNIS Pharma AG announced the results of the 2008/2009 fiscal year, which ended on 31 March 2009 and presented the milestones of the reporting period. On the way to becoming a product-based pharmaceutical company specialising in the treatment of disorders of the central nervous system (CNS), SYGNIS has taken further steps forward. One of the key milestones of the reporting period is the completion of the preparations for the multinational phase…

Article - 10/06/2009

Colleagues who became customers

Should they work with a long-standing cooperation partner or should they set up another company that was the decision faced by the staff of the Discovery-IT department of Nycomed formerly ALTANA Pharma in the spring of 2007.

Vetter Pharma-Fertigung GmbH Co. KG have announced the establishment of a new subsidiairy Vetter Pharma International GmbH VPI. The launch is scheduled for April 1st 2009. Peter Sölkner will be the Managing Director and is one of three Vetter managers appointed since June 2008.

Press release - 26/03/2009

Sygnis Pharma AG increases capital

SYGNIS Pharma AG reported its financial results for the first nine months of the fiscal year 20082009. The company improved its cash position significantly as a result of a successful capital increase. Following the capital increase the stake of dievini Hopp BioTech in SYGNIS Pharma AG increased to approximately 44.90 of the total share capital. The preparations for the phase II efficacy trial of its lead candidate AX200 in acute ischemic stroke…

The German Cancer Research Centre and Bayer Schering Pharma AG signed an agreement to establish a strategic research alliance. The partners will invest a total of 3.5 million euros in cooperative cancer research over the next two years.

Dr. Pitter Huesgen Dr. Michael Strerath and Dr. Carl Kübler have been awarded this years Nycomed Award. The Award which is worth a total of 15000 distinguishes outstanding doctoral theses in the fields of biology chemistry and physics.

Karen Grave-Hermann and Dr. Robert Hermann founded cr.applications in 2003. The two specialists who have wide-ranging experience in drug development talked to Michael Statnik about current trends in their field and about the development of the German biotech sector.

The 14th annual edition of BIO-Europe which toke place in Mannheim strengthened its claim to being the worlds largest stand-alone partnering event with the participation of 1250 biotech pharma and professional service organizationsa and 190 company presentations.

Press release - 15/10/2008

Hans-Jürgen Apell - insights into active ion transport

Biophysicist Prof. Hans-Jürgen Apell carries out basic research at the University of Constance in order to elucidate the molecular mechanisms involved in the transport of ions through membranes and to come up with important findings for new therapeutic concepts. His major field of research focuses on structure-function relationships of P-type ATPases enzymes which cleave ATP adenosine triphosphate and transport ions thereby resulting in muscle…

Genedata AG has developed a modular software system known as Genedata Screener that is tailored to screening and hit-to-lead applications. Dr. Timo Wittenberg who works at the companys site in Constance Germany told us about the advantages of the software for identifying high-potential leads.

SYGNIS Pharma AG announced that it has received a positive recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency for AX200 in the treatment of spinal cord injury.

The Early Discovery department of the research-based pharmaceutical company Nycomed GmbH deals with early drug research from the identification of targets to the generation of lead structures. This process involves high-throughput drug screening. On behalf of www.bio-pro.de Michael Statnik talked with Dr. Stefanie Polej about the process of the automated analysis of molecule activities in the Constance-based company.

The Lake Constance region offers a broad range of cancer therapies and is home to several institutes and companies that are dealing with cancer research. The BioLAGO biotechnology network offers them a joint platform for co-operation and exchange of information.

Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomeds strategic decision not to further invest in oncology RD activities.

About a year ago Prof. Dr. Martin Schwemmle and his team at the University Hospital of Freiburg discovered a new starting point in the fight against the H5N1-virus. In the meantime the scientists are working together with the company Pike Pharma to develop a compound.

Press release - 09/07/2008

Rentschler to focus on biotechnology

Rentschler has sold all its Rentschler Pharma GmbH shares to RIEMSER AG in Greifswald. With this move Rentschler is concentrating all its biotech activities at one site and thus providing the framework for further growth. In 2006 Rentschler sold its self-medication business.

The new drug screening and safety pharmacology laboratory at NMI Technologie Transfer GmbH NMI TT GmbH in Reutlingen with its standardised and special test systems complies fully with the requirements of safety pharmacology tests.

In the first quarter of 2008 Nycomeds adjusted EBITDA increased by 6.2 to 304.0 million compared to 286.3 million in the first quarter of 2007 benefiting from the cost decreasing effects of last years restructuring.

Vetters top management team is once again complete. As of June 1st 2008 Peter Soelkner will be heading a number of divisions at the Ravensburg-based company which specialises in the aseptic filling of prefilled injection systems. His new tasks will include Global Key Account Management Corporate Marketing Supply Chain Management and Project Management.